Security
YD Bio Limited Ordinary Shares · YDES
YDESNASDAQCommon stockCurrentCIK 2011674Updated Oct 7, 2026
Name history
True Velocity, Inc./DE · through Jun 21, 2024
YDES price & chart
Loading TradingView…
NASDAQ:YDES on TradingView ↗About the company
YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation - based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.
In the news
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | — | — | 13,779,397Source | 6,864,226Source |
| Property, Plant and Equipment, NetUSD | — | — | 59,340Source | 64,379Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | 2,609,739Source | 2,680,035Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | 6,007,615Source | 3,132,298Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 167,477Source | 86,582Source |
| Inventory, NetUSD | — | — | 1,879,542Source | 37,335Source |
| Assets, CurrentUSD | — | — | 9,670,190Source | 3,467,882Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 1,324,016Source | 194,740Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 8,470Source | 23,698Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 67,680Source | — | 16,635,060Source | 273,980Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | — | — | 7,079Source | 6,473Source |
| Retained Earnings (Accumulated Deficit)USD | -67,680Source | — | -10,238,359Source | -1,927,043Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 213,936Source | 45,072Source |
| Stockholders' Equity Attributable to ParentUSD | -67,680Source | 0Source | -2,855,663Source | 6,590,246Source |
| Additional Paid in Capital, Common StockUSD | — | — | 7,161,681Source | 8,465,744Source |
| Liabilities and EquityUSD | — | — | 13,779,397Source | 6,864,226Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | — | — | 1,643,578Source | 263,060Source |
| Operating Lease, Liability, CurrentUSD | — | — | 6,764Source | 16,581Source |
| Accounts Payable, CurrentUSD | — | — | 413,290Source | 26,866Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | 5,684Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | 1,463Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | 403,445Source | 151,392Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | 1,463Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts ReceivableUSD | 84,298Source | -6,297Source |
| Increase (Decrease) in InventoriesUSD | 1,842,207Source | -28,517Source |
| Deferred Income Tax Expense (Benefit)USD | -1,463Source | 26,576Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -6,596,706Source | -1,222,681Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,440,019Source | -2,900,670Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,440,019Source | 74,914Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,869,150Source | 7,113,509Source |
| Repayments of Long-term DebtUSD | — | 32,977Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,875,317Source | 3,045,200Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,007,615Source | 3,132,298Source |
| Supplemental disclosure of cash flow information: | ||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 772Source |
| Additional Financial Items | ||
| AmortizationUSD | 193,314Source | 94,536Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | 2,450,000Source | — |
| Deferred Other Tax Expense (Benefit)USD | -1,531Source | -95Source |
| DepreciationUSD | 16,246Source | 10,199Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -109Source | — |
| General and Administrative ExpenseUSD | 3,663,141Source | 1,124,469Source |
| Income Tax Expense (Benefit)USD | -1,531Source | 25,080Source |
| InterestExpenseNonoperatingUSD | — | 772Source |
| Investment Income, InterestUSD | 80,162Source | 11,808Source |
| Net Income (Loss) Attributable to ParentUSD | -8,311,316Source | -1,411,559Source |
| Nonoperating Income (Expense)USD | -3,041,126Source | 75,451Source |
| Operating ExpensesUSD | 5,439,131Source | 1,617,286Source |
| Operating Lease, ExpenseUSD | 20,471Source | 11,731Source |
| Other Nonoperating Income (Expense)USD | 46,803Source | 64,415Source |
| Proceeds from Contributions from AffiliatesUSD | — | 314,409Source |
| Proceeds from Issuance of Common StockUSD | 13,200,000Source | 7,545,772Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 596,817Source | 510,360Source |
| Cost of Goods and Services Sold | —Source | —Source |
| Operating Income (Loss)USD | -5,271,721Source | -1,461,930Source |
| Other Nonoperating Income (Expense)USD | 46,803Source | 64,415Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -8,312,847Source | -1,386,479Source |
| Income Tax Expense (Benefit)USD | -1,531Source | 25,080Source |
| Net Income (Loss) Attributable to ParentUSD | -8,311,316Source | -1,411,559Source |
| Earnings Per Share, BasicUSD per share | -0.12Source | -0.02Source |
| Earnings Per Share, DilutedUSD per share | -0.12Source | -0.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 66,719,177Source | 64,730,411Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 66,719,177Source | 64,730,411Source |
| Interest Expense (non-operating)USD | — | 772Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 3,663,141Source | 1,124,469Source |
| Gross ProfitUSD | 167,410Source | 155,356Source |
| Investment Income, InterestUSD | 80,162Source | 11,808Source |
| Nonoperating Income (Expense)USD | -3,041,126Source | 75,451Source |
| Operating ExpensesUSD | 5,439,131Source | 1,617,286Source |
| Operating Lease, ExpenseUSD | 20,471Source | 11,731Source |
| Research and Development ExpenseUSD | 1,602,064Source | 491,353Source |
| Selling and Marketing ExpenseUSD | 170,523Source | 1,957Source |
Offerings
Registration 333-290471
Filing attachments
ea030356301ex99-1.htm · 6-K · 2026-09-01
Exhibit 99.1 YD BIO LIMITED INDEX TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Pages Unaudited Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 1 Unaudited Consolidated Statements of Operations and Comprehensive Income/(Loss) for the Six Months Ended June 30, 2026 and 2…
Read attachment ↗ea030356301ex99-2.htm · 6-K · 2026-09-01
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS References in this report (this “Report”) to “we,” “us” or the “Company” refer to YD Bio Limited, a Cayman Islands exempted company, and its consolidated subsidiaries. References to our “management” or our “management team” refer to our officers and directors. The following discussion and analysis of the our financial condition and results of operations should be read in conjunction with the unau…
Read attachment ↗ea030149801ex99-1.htm · 6-K · 2026-08-11
Exhibit 99.1 YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute Two chrono-nutrition formulations - a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula - were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to expand this approach by exploring additional opportun…
Read attachment ↗ea028862401ex99-1.htm · 6-K · 2026-05-01
Exhibit 99.1 YD Bio Limited Reports Full Year 2025 Financial Results TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025. Management Commentary “2025 was a highly transformative and foundational year for YD Bio, characterized by the successfu…
Read attachment ↗ea028616001ex4-15.htm · 20-F · 2026-04-30
Exhibit 4.15 LETTER OF INTENT ۞է㫮 BETWEEN: ॹ㫮ы The Buyer : YD Bio Limited (NASDAQ : YDES), a company incorporated in the Cayman Islands. Registered Address : 89 Nexus Way, Camana Bay, Grand Cayman, KY 1 - 9009, Cayman Islands. 嶮ސ YD Bio Limited ͧ NASDAQ : Y DE S ͨ ͧ љЈ丼䱺 澨 嶮ސ 澩 ͨ ͫ ▲؟֨旇৩㉙ 孧⡹ख孄 ͧ Ҹ՛֪֭ 89 Nexus Way, Camana Bay, Grand Cayman, KY 1 - 9009, Cayman I s lands ͨ 澞 The Seller : Safe Save Medical Cell Sciences & Technology Co., Ltd. ("SSMC"), a company incorporated in the Republic…
Read attachment ↗ea028616001ex4-16.htm · 20-F · 2026-04-30
Exhibit 4.16 MASTER STRATEGIC ALLIANCE AGREEMENT This Master Strategic Alliance Agreement (the “Agreement”) is entered into as of 2026/02/24(the “Effective Date”), by and between: YC Biotech Co., Ltd., a company organized under the laws of Taiwan, and YD Bio USA, Inc., a corporation organized under the laws of the United States. YC Biotech Co., Ltd. and YD Bio USA, Inc. are hereinafter individually referred to as a “Party” and collectively as the “Parties.” 1. Purpose of Alliance The Part…
Read attachment ↗